You are here

Patterned, Responsive Cellular Therapies Using Novel Mammalian Cellular Regulator Systems

Award Information
Agency: Department of Defense
Branch: Defense Advanced Research Projects Agency
Contract: 140D0420C0057
Agency Tracking Number: DHR001119S0035-16-0001
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: HR001119S0035-16
Solicitation Number: DARPA HR001119S0035-16
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-02-05
Award End Date (Contract End Date): 2021-03-09
Small Business Information
108 Fayerweather St. #2
Cambridge, MA 02138
United States
DUNS: 116969787
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Robert Rogers Yocum
 (781) 572-0120
Business Contact
 Robert Yocum
Phone: (781) 572-0120
Research Institution
 General Biologics, Inc.
 Robert Rogers Yocum Robert Rogers Yocum
108 Fayersweather St. #2
Cambridge, MA 02138
United States

 (781) 572-0120
 Nonprofit College or University

We propose to design, build and test genetic circuits and DNA constructs that will be expressed in human cells and that will ultimately have applications for the health of warfighters. The circuits will have physiological inputs representing, for example, (1) infection/sepsis, (2) altitude sickness or blood loss, and (3) radiation exposure; which will be mediated through signal transduction pathways initiated by inflammatory cytokines, hypoxia, and DNA damage. The circuit outputs will be secreted proteins that are adaptive for each of these physiological states, such as (a) antibodies that inhibit damaging cytokines and (b) pro-survival proteins that prevent cell death in response to trauma (particularly neuronal death). The DNA constructs will contain multiple circuits that will be activated independently, using distinct promoters, enhancers, and insulating elements to insure functional separation. The DNA constructs will be designed for administration to warfighters either by gene therapy or withdrawal of cells, engineering the cells in vitro, and return of engineered cells into the warfighter. The constructs will also contain circuits that allow for killing of engineered cells after their utility has expired. The constructs will not integrate into the genome and either not replicate at all or replicate only during phases of need.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government